Tor 25 jul / År 42 / Nr 3 2024

SORBACT – a unique antimicrobial product

Within an alarmingly short timeframe of only ten years, presumably no real new antibiotics will be available to treat the most resistant bacteria according to recently presented data from Region Skåne, Sweden. The Swedish pharmaceutical and medical technology company ABIGO Medical AB has a unique and patented wound care product line, Sorbact, which speeds up healing and binds bacteria without the risks of resistance development. This is based on a different and unique mechanism, the Sorbact method, developed to improve wound care. The product range is internationally available, as per today in 65 countries, with recent introduction in the United States.

The development of Sorbact is initially based on the work of two senior Swedish professors, Torkel Wadström and Stellan Hjertén. ABIGO Medical realised the importance of their work and took on the challenge of further developing this unique product concept, along with investment costs, and successfully commercialised a range of products internationally. All manufacturing takes place in the company’s own factory located in Askersund, Örebro county. Headquarters are located in Gothenburg, on the west side of the country.
ABIGO is wholly owned by the two brothers, Leif Smith and Jan G. Smith, both actively involved in the day-to-day running of the company, and successfully spreading a genuine entrepreneurial spirit thus creating an inspirational atmosphere in which employees thrive. “Research and development, unique products, internationalisation, expansion and long-term sustainability are key words for us”, Jan G. Smith underlines.

10 million SEK to be invested in production facility
The Askersund facility is the only full-scale unit for manufacturing advanced wound healing products in Sweden. The plant, which was inaugurated in 2008 by the Minister for Health and Social Affairs Göran Hägglund, is expanding rapidly, and is already pretty crowded.
“We are currently investing more than 10 million Swedish kronor in new technology and state-of-the-art machinery as well as a comprehensive extension of the premises. We have identified a substantial need to increase capacity in order to meet future demand”, Jan G. Smith explains.

Complete partner with bright future
There are many exciting and thriving companies making up the Swedish Life Science industry and ABIGO Medical is definitely one of them. The company is still relatively unknown to the general public, but its unique wound care products are today being more and more respected and known internationally. ABIGO Medical has, with in-house research and development and complete production facilities, a strong foothold on the Swedish as well as the international market for new and innovative life science products.
Being able to treat wounds and infections effectively without the use of antibiotics is an important step in order to overcome the accelerating problem with multi-resistant bacteria. ABIGO’s ambition is to become one of the leading international companies in the field and the firm is well on the way.
“Our research holds high class and will no doubt lead to further introductions of new, innovative solutions for effective wound care in upcoming years”, Jan G. Smith concludes.